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Abstract Sixty-four cases of malignant lymphoma involving
the liver were examined. Of these, 20 cases were histologically
confirmed to be primary hepatic B-cell lymphoma. Twelve of
these 20 cases were diffuse large B-cell lymphoma (DLBCL)
and eight cases were mucosa-associated lymphoid tissue
(MALT) lymphoma. Of the 12 cases of DLBCL, six were
immunohistologically positive for CD10 and/or Bcl6 (indicat-
ing a germinal center phenotype), six were positive for Bcl2,
and five were positive for CD25. Eight of the 12 DLBCL cases
(66.7%) and two of the eight MALT lymphoma cases (25%)
had serum anti-hepatitis C virus (HCV) antibodies and HCV
RNA. The incidence of HCVinfection was significantly higher
in the hepatic DLBCL cases than in systemic intravascular
large B-cell cases with liver involvement (one of 11 cases,
9.1%) and T/NK-cell lymphoma cases (one of 19 cases,
5.3%) (p<0.01 for both). Two hepatic DLBCL cases (16.7%)
had rheumatoid arthritis treated with methotrexate, and four
MALT lymphoma cases (50%) had Sjögren’s syndrome, pri-
mary biliary cirrhosis, or autoimmune hepatitis; one case in
each of these two groups was complicated by chronic HCV-
seropositive hepatitis. Although primary hepatic lymphoma is
rare, persistent inflammatory processes associated with HCV
infection or autoimmune disease may play independent roles in
the lymphomagenesis of hepatic B cells.
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Introduction
B-cell lymphoma in hepatitis C virus (HCV)-seropositive
patients frequently presents with extranodal disease in the bone
marrow, major salivary glands, or spleen [1, 2]. Although
diffuse large B-cell lymphoma (DLBCL) is frequent in HCV-
seropositive B-cell lymphoma patients, a significantly higher
incidence of lymphoplasmacytic lymphoma than HCV-
negative B-cell lymphoma has been reported (43 of 257 cases,
16.7%versus91of1118cases,8%;p<0.01)[3].Hermineetal.
[4] described nine French HCV-seropositive cases of splenic
marginalzonelymphomawithmonoclonalIgMandpolyclonal
IgG(typeII)cryoglobulinemia,andreportedthatallthesecases
showed loss of serum HCV RNA and complete remission of
lymphoma after treatment with interferon-α and ribavirin.
HCV infection and associated type II cryoglobulinemia may
induce B-cell lymphoid neoplasia.
The HCV core protein has been shown to induce prolif-
eration of human B-cell lines through up-regulation of spe-
cific B-cell-related genes and reduction in apoptosis [5, 6].
The levels of the activation-induced cytidine deaminase
protein and gene, which provide a key enzyme for somatic
hypermutation of germinal center (GC) B cells, were dra-
matically increased in peripheral blood B cells in patients
with HCV-seropositive hepatitis [7]. HCV transgenic mice
expressing the full HCV genome in B cells showed a high
incidence of CD25 [interleukin-2α receptor (IL2αR)]-
positive DLBCL as well as elevated serum levels of IL2αR
[8]. HCV infection may play a role in the multistep mech-
anism of lymphomagenesis in peripheral B cells.
Ramos-Casals et al. [9] reported 25 cases of B-cell lympho-
ma with HCV infection and Sjögren’s syndrome (SS), which
showed frequent type II cryoglobulinemia (80%), extranodal
tumor invasion (60%) including in the liver (16%), mucosa-
associated lymphoid tissue (MALT) lymphoma (44%), and
DLBCL (24%). Primary biliary cirrhosis (PBC) has been
reported to occasionally be complicated by HCV infection
(14 of 170 cases, 8.2%), but not by lymphoma [10]. Autoim-
mune disease with or without HCV infection may play a role
in primary hepatic lymphoma.
Primary hepatic B-cell lymphoma is rare, representing
0.06% of all non-Hodgkin’sl y m p h o m a[ 11]. Page et al. [11]
reported 23 cases of primary hepatic DLBCL and one of
MALT lymphoma, of which six of the 10 examined DLBCL
cases (60%) had HCV infection. Persistent HCV infection
often complicates cases of primary hepatic DLBCL. We se-
lected 20 cases of primary hepatic B-cell lymphoma from an
area of Japan in which HCV infection is endemic. Of these,
eight of 12 DLBCL cases (66.7%) and two of eight MALT
lymphoma cases (25%) had serum anti-HCV antibodies and
HCVRNA,andsixDLBCLcasesandfourMALTlymphoma
cases had autoimmune disease. We examined clinicopatho-
logical characteristics and etiological factors in patients with
primary hepatic B-cell lymphoma, especially cases with HCV
infection and autoimmune disease.
Materials and methods
Case selection
We reviewed the 5220 cases of malignant lymphoma in our
register from 1995 to 2010, and included the 64 cases with
histologically confirmed liver involvement at initial presen-
tation in this study. Primary hepatic B-cell lymphoma was
defined as extranodal lymphoma of the liver, with the bulk
of the disease localized to this site [12]. Contiguous lymph
node and perihepatic metastasis may be seen in primary
hepatic B-cell lymphoma, as in gastrointestinal extranodal
B-cell lymphoma [13, 14]. Histological diagnosis was
according to the World Health Organization classification
[13]. Twenty of 5,220 cases (0.4%) had clinical stage I or II
primary hepatic lymphoma without superficial lymphade-
nopathy. The other 44 cases with liver involvement had
malignant lymphoma with systemic or secondary intrahe-
patic tumor invasion as well as extrahepatic tumors or
superficial nodal invasion. These 44 cases were used as a
control group, comprising 22 cases of systemic B-cell lym-
phoma [12 cases of intravascular large B-cell lymphoma
(IVLBCL) and 10 cases of DLBCL] and 22 cases of
T/NK-cell lymphoma (nine cases of hepatosplenic T-cell
lymphoma, seven cases of adult T-cell leukemia/lymphoma
(ATL/L), four cases of aggressive NK-cell leukemia/lym-
phoma, and two cases of other T-cell lymphoma). In an
additional control study, the seven cases of primary hepatic
reactive lymphoid hyperplasia [14] were also examined to
check for HCV infection and autoimmune disease.
The clinical and laboratory findings, treatment, and prog-
nosis of patients presenting to ten hospitals were examined.
Tumor stages were classified according to the modified Ann
Arbor staging system [15].
Examination for HCVand HBV infections
Serum samples were screened for HCV infection by mea-
suring anti-HCV antibody levels using the second genera-
tion enzyme-linked immunosorbent assay (ELISA)
technique (Abbott Laboratories, Chicago, IL, USA). If pos-
itive, a PCR-based technique (PCR Amplicor; Roche,
Branchburg, NJ, USA) was used to detect HCV RNA. The
HCV core genotype was determined using PCR-based tech-
niques (SMI test HCV genotyping kit; Sumitomo Metals,
380 Virchows Arch (2012) 460:379–387Osaka, Japan), which identified six genotypes according to
the Simmonds classification: 1A, 1B, 2A, 2B, 3A, and 3B.
HBV surface (HBs) and envelope (HBe) antigens were
detected using an ELISA kit (Abbott Laboratories, Abbott
Park, IL, USA) [16].
Histology and immunohistology
Biopsy and surgical specimens were fixed with 20% forma-
lin, embedded in paraffin, and stained with hematoxylin and
eosin. The hepatic lesions of all 71 cases were examined
histologically, including 16 autopsy cases (two primary
hepatic DLBCL cases, two IVLBCL cases, and 12 T/NK-
cell lymphoma cases). Immunohistological examination was
performed by applying a panel of monoclonal and polyclon-
al antibodies to formalin-fixed tumor samples using the
ChemMate Envision method (DakoCytomation, Glostrup,
Denmark), and the peroxidase color reaction was developed
using diaminobenzidine as the substrate. Antibody, clone,
and source were as follows: CD3 (PS1, Novocastra, UK),
CD5 (4C7, Novocastra), CD10 (56C6, Novocastra), CD20
(L26, Dako, USA), CD23 (1B23, Novocastra), IL2α recep-
tor (CD25, 4C9, Novocastra), CD30 (BerH2, Dako), Bcl1
(5D4, IBL, Japan), Bcl2 (124, Dako), Bcl6 (P1F6, Novo-
castra), multiple myeloma 1 (MUM1p, Dako), anti-HBs
antigen (ZCH16, Nichirei, Japan), and IgG4 (HP6026,
Zymed, USA).
In situ hybridization for detection of Epstein–Barr
virus-encoded RNA (EBER)
Deparaffinized tissue sections were digested with proteinase
K and hybridized in a solution of 50% formamide containing
fluorescein isothiocyanate (FITC)-labeled EBER oligonucleo-
tides using a Dako hybridization kit (DakoCytomation,
Glostrup, Denmark). Hybridization products were detected
using rabbit anti-FITC antibody, then incubated with Chem-
Mate Envision and colored with DAB.
Statistical analyses
Univariate analyses were performed using the chi-square and
Fisher’s tests to determine differences between the two ma-
lignant lymphoma groups. Fifty-four node-based DLBCL
cases and 445 colon cancer cases admitted to the National
Kyushu Medical Center were selected for examination of
HCV and HBV infections as a control group. Prognosis was
determined by calculating the cumulative survival time of 53
casesusingtheKaplan–Meiermethodandwasanalyzedusing
the log-rank and generalized Wilcoxon tests.
Selection of 36 previously reported primary hepatic B-cell
lymphoma cases
Sixteen primary DLBCL cases and 20 MALT lymphoma
cases, which had each been described in detail, were selected
from 27 reports in the English literature from 1990 to 2010
[17–42]. The clinical and histological details of these 36 cases
were determined from the reported findings by the
corresponding laboratory.
Results
Clinical findings, laboratory data, and outcomes
The clinical data at initial presentation of the 20 cases of
primary hepatic lymphoma, 44 cases of systemic B- and T/
NK-cell lymphoma with liver involvement, and seven cases of
reactive lymphoid hyperplasia are shown in Table 1.T w e l v e
cases had primary hepatic DLBCL. Eight of these 12 cases
(66.7%) had serum anti-HCVantibodies, and HCV RNAwas
detected in all six of these cases examined. Two of these cases
wereinfected with genotype 1band two with genotype 2a.The
prevalence of anti-HCV antibody positivity was significantly
higher in DLBCL cases (66.7%) than in cases of systemic
IVLBCL (one of 11, 9.1%), systemic T/NK-cell lymphoma
(one of 19, 5.3%), nodal DLBCL (five of 54, 9.3%), and colon
cancer (23 of 445, 5.2%) (p<0.01). Two other DLBCL cases
(16.7%) had HBs and HBe antigens, but this prevalence was
not significantly higher than in cases of systemic IVLBCL
(one of 11, 9.1%), nodal DLBCL (one of 54, 1.9%), or colon
cancer (seven of 445, 1.6%). Eight cases had primary hepatic
MALT lymphoma. Two of these cases (25%) were positive for
serum anti-HCVantibodies and HCV RNA, and were infected
with genotype 1b. This HCV prevalence was not significantly
higher than in the other four tumor groups described above. In
the other two groups of patients with systemic B-cell lympho-
ma, five of the ten DLBCL cases (50%) had anti-HCV anti-
bodies. One case (14.3%) with reactive lymphoid hyperplasia
had HCV infection. There were no cases with co-infection of
HCVand HBV.
Detailed clinicopathological findings of the primary he-
patic and systemic B-cell lymphoma cases are shown in
Table 2. Of the cases with primary hepatic DLBCL, five
had chronic hepatitis, three had liver cirrhosis, and one had
chronic hepatitis and hepatocellular carcinoma. The remain-
ing case was an HCV carrier. Two cases had rheumatoid
arthritis which had been treated with methotrexate for 7 and
10 years, respectively, and one case had chronic HCV
hepatitis. Seven cases were classified as clinical stage I
and five were classified as II1 or II2. Combined chemother-
apy was administered in nine cases. The five cases who
underwent rituximab plus cytotoxic treatment were alive
Virchows Arch (2012) 460:379–387 381and well at 21 to 72 months after treatment initiation, while
three of the four cases who received only cytotoxic treat-
ment died of disease with extrahepatic tumor invasion. The
median survival time of these nine treated cases was
27 months, and the 5-year overall survival rate was 44%.
Two cases did not receive cytotoxic treatment and died of
hepatic failure. Limited intrahepatic lymphoma was found at
autopsy. The remaining case was lost to follow-up after
3 months.
All eight cases of primary hepatic MALT lymphoma had
a single hepatic tumor (Fig. 1). Two cases had SS, one had
SS and PBC, and one had autoimmune hepatitis. All these
cases received surgery and/or cytotoxic treatment with or
without rituximab, and were alive and well at 5 to 84 months
after treatment initiation. Their median survival time was
longer than 84 months, which was significantly longer than
that of primary hepatic DLBCL cases (p<0.05) (Fig. 2).
In cases of systemic lymphoma with liver involvement,
only one of 12 IVLBCL cases (8.3%) had systemic lupus
erythematosus. The prevalence of autoimmune disease
was significantly lower in IVLBCL cases than in primary
hepatic lymphoma cases (six of 20 cases, 30%; p<0.05).
The median survival time of the seven IVLBCL cases for
which this information was available was 6 months,
which was significantly shorter than in primary hepatic
DLBCL cases (p<0.01). Of the ten cases with systemic
DLBCL, four patients with anti-HCV antibodies died of
disease within 6 months. The median survival time of
these ten cases was 13 months, which was significantly
shorter than in primary hepatic DLBCL cases (p<0.05).
Of the 22 cases of systemic T/NK-cell lymphoma, one
c a s ew i t hT - L G Ll e u k e m i a( 5 . 3 % )h a dP B C .O n ec a s e
with reactive lymphoid hyperplasia (14.3%) was compli-
cated by PBC.
Table 1 Initial clinical data of
71 cases of liver-involving lym-
phoproliferative disease
/: positive/examined cases. HCV
hepatitis C virus, HB hepatitis B,
HTLV human T-cell lympho-
tropic virus, DLBCL diffuse
large B-cell lymphoma, MALT
mucosa-associated lymphoid tis-
sue, IVLBCL intravascular large
B-cell lymphoma
No. of
cases
Age
(mean)
M/F Histological
type: no. of cases
Anti-HCVAb HBs, e Ag Anti-HTLV-1 Ab
Primary hepatic B-cell lymphoma
20 64 years old 10:2 DLBCL: 12 8 (66.7%) 2 (16.7%) 1 (8.3%)
3:5 MALT: 8 2 (25%) 1 (12.5%) 0/5 (0)
Total 13:7 10 (50%) 3 (15%) 1/17 (5.9%)
Liver-involving systemic B-cell lymphoma
22 67 years old 7:5 IVLBCL: 12 1/11 (9.1%) 1/11 (9.1%) 1/10 (10%)
5:5 DLBCL: 10 5 (50%) 1 (10%) 0/7 (0)
Total 12:10 6/21 (29%) 2/21 (9.5%) 1/17 (5.9%)
Liver-involving systematic T/NK-cell lymphoma
22 55 years old 17:5 1/19 (5.3%) 0/19 (0) 7/21 (33.3%)
Reactive lymphoid hyperplasia
7 61 years old 0:7 1(14.3%) 0 (0) 0 (0)
Table 2 Detailed clinicopathological findings and prognosis in 42 of liver-involving B-cell lymphoma
Histological type Clinical stage Liver disease Hepatic tumors Complication Median survival (months)
I/II/III/IV CH LC HCC Single Multiple Diffuse
Primary hepatic B-cell lymphoma
DLBCL: 12 7/5/0//0 5 3 1 8 4 0 RA: 2 27
MALT: 8 8/0/0//0 3 1 1 8 0 0 SS: 2, PBC: 1
a, AH: 1 >84
Total: 20 15/5/0//0 8 4 2 16 4 0 6
Liver-involving systemic B-cell lymphoma
IVLBCL: 12 0/0/0//12 1 0 0 0 0 12 SLE: 1 6
DLBCL: 10 0/0/0//10 5 0 0 2 8 0 0 13
Total 22 0/0/0//22 6 0 0 2 8 12 1
DLBCL diffuse large B-cell lymphoma, MALT mucosa-associated lymphoid tissue, IVLBCL intravascular large B-cell lymphoma, CH chronic
hepatitis, LC liver cirrhosis, HCC hepatocellular carcinoma, RA rheumatoid arthritis, SS Sjögren’s syndrome, PBC primary biliary cirrhosis, AH
autoimmune hepatitis, SLE systemic lupus erythematosus
aOne patient complicates PBC and SS
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The immunohistological characteristics of the primary he-
patic and systemic B-cell lymphoma cases are shown in
Table 3. Demarcated tumors were detected histologically
in all of the cases of primary hepatic DLBCL and MALT
lymphoma (Fig. 3), and no intrasinusoidal tumor invasion
was found. A few atrophic reactive lymph follicles were
detected in the tumors of all 20 cases. The lymphoma cells
in the 12 primary hepatic DLBCL cases were positive for
the following antigens (number of positive cases, % of
total): CD10 (4, 33.3%), Bcl2 (6, 50%), Bcl6 (5, 41.7%),
MUM1 (5, 41.7%), and CD25 (5, 41.7%) (Fig. 4a–c). Six
cases had a GC B-cell phenotype. Three cases were CD5-
positive and Bcl1-negative. In situ hybridization indicated
nuclear EBER signals in two primary hepatic DLBCL cases
(16.7%) which were complicated by rheumatic arthritis
(Fig. 4d).
The lymphoma cells of all eight MALT lymphoma cases
were positive for Bcl2 and negative for CD5, CD23, CD10,
Bcl6, MUM1, and CD25. No positive reaction to HBs
antigen (ZCH16) was detected in the lymphoma cells of
the three primary lymphoma cases who were HBs-antigen
seropositive. No increase in IgG4-positive plasma cells was
detected in any cases of hepatic DLBCL, MALT lymphoma,
or reactive lymphoid hyperplasia.
Of the systemic B-cell lymphoma cases, all 12 IVLBCL
cases had an intrasinusoidal growth pattern of lymphoma
cells, and ten cases (83.3%) had MUM1-positive lymphoma
cells. Eight of ten systemic DLBCL cases (80%) were
positive for MUM1 and three cases (33.3%) were positive
for CD25.
Findings of 36 previously reported of primary hepatic B-cell
lymphoma cases
Sixteen of the previously reported cases were DLBCL and
20 cases were MALT lymphoma [17–42]. Of the 16
DLBCL cases, nine (56.3%) were HCV-seropositive and
four (25%) were HBV-seropositive. Only one DLBCL case
had both HCV infection and SS. The median survival time
of the ten DLBCL cases examined was 48 months. Nine of
the 20 MALT lymphoma cases (45%) were HCV-
seropositive and two cases (10%) were HBV-seropositive.
Three MALT lymphoma cases had PBC, one had SS, and
one had both PBC and SS, and these five cases (25%) did
not have HCV nor HBVinfection. The median survival time
of the 18 MALT lymphoma cases for which this information
was available was 65 months, which was significantly lon-
ger than in the above-reported ten DLBCL cases (p<0.05).
Discussion
The prevalence of HCVinfection was significantly higher in
the 12 primary hepatic DLBCL cases examined (66.7%)
than in the systemic lymphoma cases with liver involve-
ment, as well as in the other two control groups (p<0.01).
Two MALT lymphoma cases examined (25%) had chronic
HCV-positive hepatitis. Bronowicki et al. [43]r e p o r t e d
HCV infection in four of 21 primary hepatic DLBCL cases
(19%), but no HCV infection in three MALT lymphoma
cases. Among the previously reported cases [17–42], nine of
16 primary hepatic DLBCL cases (56.3%) and nine of 20
MALT lymphoma cases (45%) had HCV infection. Al-
though the prevalence of HCV infection was low in the
MALT lymphoma cases that we examined, our results are
consistent with those of other reports [11, 43] examining the
relationship between HCV infection and primary hepatic
DLBCL. Intracytoplasmic HCV RNA signals have been
detected in hepatocytes, mononuclear cells, and lymph
Fig. 1 Macroscopic appearance of a primary hepatic MALT lympho-
ma without HCVinfection. Awhitish nodular tumor is seen in the liver
Fig. 2 Actuarial survival curves of cases of primary hepatic DLBCL
and MALT lymphoma, intravascular and systemic large B-cell lym-
phoma, and systemic T/NK-cell lymphoma with liver involvement.
Primary hepatic MALT lymphoma cases have a significantly better
prognosis than primary hepatic DLBCL cases (p<0.05). Primary he-
patic DLBCL cases have a significantly better prognosis than cases of
intravascular large B-cell lymphoma, systemic DLBCL, and systemic
T/NK-cell lymphoma (p<0.01 or <0.05)
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in situ hybridization [44]. Sung et al. [45] established a cell
line of an HCV-seropositive B-cell lymphoma, from which
they extracted HCV viral particles with which they were
able to infect other B-cell lines as well as hepatocytes.
Kasama et al. [8] demonstrated expression of the full HCV
genome in B cells of HCV transgenic mice, and 25% of
these mice progressed to DLBCL within 600 days after
birth. These reports support the theory that HCV can infect
reactive and neoplastic B cells, and that persistent HCV
infection may induce primary hepatic as well as other organ
B-cell lymphoma.
Of the eight HCV-seropositive primary hepatic DLBCL
cases examined, five were classified as CD10- and/or Bcl6-
positive GC B-cell phenotype. Expression of Bcl2 and
CD25 (IL2αR) was detected in the lymphoma cells of four
of these eight DLBCL cases. HCV infection has been
reported to cause an approximately 5- to 10-fold increase
in the mutation frequency of the Bcl6 gene in peripheral
blood mononuclear cells, B-cell lymphoma cells, and their
cell lines [46]. Zuckerman et al. [47] reported a significantly
higher incidence of Bcl2 gene translocation in peripheral
blood cells in cases with HCV-seropositive hepatitis, com-
pared with HCV-negative controls (p<0.01). Machida et al.
[48] demonstrated that disruption of interferon regulatory
factor 1 in HCV-infected mice increased serum IL-2 and
Bcl2 expression in lymphocytes, and induced a high inci-
dence of B-cell lymphoma. As well as inducing anti-
apoptotic Bcl2 and transcription factors such as Bcl6, IL-2
may activate cytokine signaling via CD25 (IL2αR) in HCV-
infected B cells [49]. Thus, lymphomagenesis may occur via
a multistep mechanism in HCV-infected GC and non-GC B
cells, even in the liver.
We found that two cases of primary hepatic DLBCL
(16.7%) had rheumatoid arthritis treated with methotrexate.
Although there were no reports of complications in these two
cases, they were consistent with iatrogenic immunodeficiency-
associated lymphoproliferative disorder [13]. Four of the eight
cases of MALT lymphoma (50%) were complicated by PBC
and/or SS or autoimmune hepatitis. Of these six cases with
autoimmune disease, one case each of DLBCL and MALT
lymphoma had chronic HCV hepatitis. Of the 36 previously
Table 3 Immunohistological findings and Epstein–Barr virus infection in 42 cases of liver-involving B-cell lymphoma
Histological type CD5 CD10 Bcl2 Bcl6 MUM1 CD25 EBERs
Primary hepatic B-cell lymphoma
DLBCL: 12 3 (25%) 4 (33.3%) 6 (50%) 5 (41.7%) 5 (41.7%) 5 (41.7%) 2 (16.7%)
MALT: 8 0/7 (0) 0 (0) 8 (100%) 0/6 (0) 0 (0) 0 (0) 0 (0)
Liver-involving systemic B-cell lymphoma
IVLBCL: 12 3/10 (30%) 0/11 (0) 8/10 (80%) 1/10 (10%) 10 (83.3%) 2 (16.7%) 0 (0)
DLBCL: 10 1/9 (11.1%) 1 (10%) 8/9 (88.9%) 2/9 (22.2%) 8 (80%) 3/9 (33.3%) 0 (0)
/: positive/examined cases. EBERs Epstein–Barr encoded RNAs, DLBCL diffuse large B-cell lymphoma, MALT mucosa-associated lymphoid
tissue, IVLBCL intravascular large B-cell lymphoma
Fig. 3 Histological appearance
of primary hepatic DLBCL (a)
and MALT lymphoma (b)i n
HCV-seropositive cases (hema-
toxylin and eosin staining, ×400).
In the DLBCL case, many small
lymphocytes are seen among
large lymphoid cells
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case and five MALT lymphoma cases (total 16.7%) were
complicated by PBC and/or SS. Of these, only one DLBCL
case had HCV infection. In Europe, SS occurs frequently in
HCV-seropositive patients with type II cryoglobulinemia,
which is highly suggestive of a prodromal stage of extranodal
low-grade B-cell lymphoma [50,51]. There is great geographic
heterogeneity in the prevalence of type II cryoglobulinemia in
HCV-seropositive cases, with type II cryoglobulinemia occur-
ring more commonly in Southern Europe (40–60% of HCV-
seropositive cases) [52]. In Japan, type III cryoglobulinemia
was found in 23 of 65 HCV-seropositive cases (35.4%), but
type II cryoglobulinemia was found in only one case (1.5%)
[53]. Japanese lymphoplasmacytic and MALT lymphoma
cases also had a low incidence of HCV infection compared
with DLBCL cases [16]. These findings support the view that
primary hepatic lymphoma, especially MALT lymphoma, can
occur in cases of autoimmune disease independently of HCV
infection and type II cryoglobulinemia in Japan.
The present study also demonstrated that HBVor EBV
infection, which are important etiological factors for
tumorigenesis, were a minor complication of primary
hepatic B-cell lymphoma cases. Hepatic reactive lym-
phoid hyperplasia and IgG4-positive plasma cells have
also been reported to have no direct relationship with
HCV infection, autoimmune disease, or primary hepatic
B-cell lymphoma [15, 54]. Although HCV infection and
autoimmune disease were frequent in Japanese cases of
primary hepatic B-cell lymphoma, they were mostly
found independently of each other. However, primary
hepatic lymphoma is rare, even in the primarily HCV-
infected liver [11, 43]. Marcucci et al. [55]p r o p o s e d
multifactorial models for lymphomagenesis in HCV-
seropositive cases, suggesting that lymphomagenesis was
c a u s e db yb o t hH C Vi n f e c t i o na n da d d i t i o n a lf a c t o r ss u c h
as other receptors (CD81 and others), EBV co-infection,
and environmental factors. The reasons for lymphoma
being rare in the liver may be related to localized lym-
phoid reactions in the portal area and to specific cytotoxic
immune reactions of pit (NK) cells in HCV infection [56].
Further studies are necessary to clarify the reasons for the
low incidence of primary hepatic lymphoma and the
mechanisms of lymphomagenesis in HCV infection.
The 5-year survival rate of the nine primary hepatic
DLBCL cases we examined was 43%, and the five
cases receiving rituximab plus cytotoxic treatment were
alive and well at the time of writing. A French lym-
phoma study demonstrated that 24 HCV-seropositive
systemic DLBCL cases had a significantly worse overall
2-year survival rate (56%) than 72 HCV-negative
DLBCL cases (80%), after matching for age and prog-
nostic factors (p00.02) [57]. However, four reported
primary hepatic DLBCL cases had a good prognosis
after cytotoxic treatment with or without rituximab
[58]. Antiviral treatment after cytotoxic treatment also
contributed to a significantly longer disease-free survival
period in 69 HCV-seropositive B-cell lymphoma cases
(p<0.05) [59]. These data strongly suggest that rituxi-
mab plus cytotoxic treatment followed by antiviral treat-
ment may result in an improved clinical outcome in
primary hepatic and systemic HCV-seropositive DLBCL
cases.
Fig. 4 HCV-seropositive
primary hepatic DLBCL. a, b, c
Immunoperoxidase staining. d
In situ hybridization, ×200. a
Many CD20-positive large
lymphoid cells show a diffuse
infiltrating pattern. b CD10-
positive large lymphoid cells
are diffusely distributed. Bile
canaliculi have focal weak
CD10-positivity in the upper
right hepatic lobule. c Large
lymphoid cells are positive for
CD25. d Many nuclear EBER
signals are detected in medium-
sized and large lymphoid cells.
Two bile ducts on the right are
preserved
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